Bayer says darolutamide shown to slow prostate cancer progression

FRANKFURT (Reuters) – Bayer said on Wednesday its drug candidate darolutamide was shown to slow the progression of certain types of prostate cancer in a late-stage trial.

Bayer is working on darolutamide jointly with Filand’s Orion.

(Reporting by Ludwig Burger, Editing by Rachel More)